GleamWall
中文EN

EDSA Edesa Biotech, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1540159 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-138.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-122.9%
ROA-102.5%
ROIC (approx.)-9,500.4%
Asset turnover—

Leverage & solvency

Liabilities / assets30.7%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-37.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue————————
R&D expense$3.96M$2.77M$1.12M$1.23M$939,067$484,306$1.02M$103,867
SG&A expense$1.56M$1.53M$1.22M$1.24M$964,676$1.15M$878,871$900,529
Operating income-$5.52M-$4.30M-$2.34M-$2.47M-$1.90M-$1.64M-$1.90M-$1.00M
Pretax income-$5.41M-$4.22M—-$2.23M-$1.75M-$1.59M—-$962,051
Income tax$0$800—$0$0$800—$0
Net income-$5.41M-$4.22M-$2.25M-$2.23M-$1.75M-$1.59M-$1.62M-$962,051
EBITDA-$5.49M-$4.27M-$2.32M-$2.44M-$1.88M-$1.61M-$1.86M-$960,190
EPS (basic)-0.60-0.49-0.28—-0.25-0.30-0.48—
EPS (diluted)————————
Balance sheet
Cash & equivalents$10.30M$10.00M$12.10M$10.79M$12.40M$13.90M$1.60M$1.04M
Current assets$10.78M$10.42M$12.72M$11.51M$12.76M$14.39M$2.07M$1.68M
PP&E, net———————$0
Intangibles$1.90M$1.93M$1.95M$1.98M$2.00M$2.03M$2.05M$2.08M
Total assets$12.72M$12.38M$14.71M$13.53M$14.80M$16.45M$4.16M$3.81M
Current liabilities$3.91M$2.19M$756,163$1.08M$672,674$914,701$1.90M$1.83M
Total liabilities$3.91M$2.19M$756,163$1.08M$672,674$914,701$1.90M$1.83M
Shareholders' equity$8.81M$10.20M$13.95M$12.45M$14.13M$15.54M$2.26M$1.98M
Shares outstanding9.63M8.89M8.33M7.14M7.02M7.02M3.47M3.25M
Cash flow statement
Operating cash flow-$3.08M-$2.02M-$2.09M-$1.72M-$1.70M-$2.38M-$1.52M-$967,039
Financing cash flow$3.45M-$8,980$3.36M$186,483$0$14.77M$2.07M-$31,435
Depreciation & amortization$25,644$25,872$25,460$25,868$25,787$24,509$43,109$44,206
Stock-based compensation$500,000$480,000$399,862$404,425$200,000$70,000$81,183$93,933

Free plan shows the latest 8 periods; Pro shows all 50 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.